COGT
Cogent Biosciences, Inc.
Biotechnology · Healthcare · United States
31.02
close · 2026-10-30
value
89
cheaper than peers89
quality
17
stronger fundamentals17
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, latest year | -6.6% | 84 |
| cash flow yield, latest year | -4.9% | 83 |
| cash flow yield, 3 years ago | -2.3% | 83 |
| cash flow yield, 2 years ago | -2.9% | 82 |
| cash flow yield, 1 year ago | -3.9% | 79 |
| earnings yield, 3 years ago | -7.7% | 78 |
| earnings yield, 1 year ago | -7.5% | 78 |
| earnings yield, 2 years ago | -7.8% | 76 |
| price to book | 11.39× | 13 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -85.7% | 33 |
| debt to equity | 39.3% | 17 |
3 of 4 measures available
Facts
| market cap | $5B |
| free cash flow | -$167.3M |
| employees | 258 |
| first trade | 2018-03-29 |
| next earnings | 2026-08-10 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -2.04 | -2.32 | -2.42 | -2.39 | not reported |
| free cash flow | -$266.0M | -$208.4M | -$156.4M | -$125.5M | not reported |
| net income | -$328.9M | -$255.9M | -$192.4M | -$140.2M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | -$7.2M | $0 | $0 | not reported | $0 |